Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer's disease patients

Future Neurology

Volumn 7, Issue 4, 2012, Pages 395-401

  Panza, Francesco ^a   Frisardi, Vincenza ^a,b   Imbimbo, Bruno P ^c   Logroscino, Giancarlo ^b   Seripa, Davide ^a   Pilotto, Alberto ^a,d   Solfrizzi, Vincenzo ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d S ANTONIO HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; amyloid ; amyloid related imaging abnormalities; bapineuzumab; passive immunotherapy

Indexed keywords

AMYLOID BETA PROTEIN; BAPINEUZUMAB; HEMOSIDERIN;

ALLELE; ALZHEIMER DISEASE; AMYLOID RELATED IMAGING ABNORMALITY; APOE EPSILON4 GENE; BRAIN EDEMA; BRAIN HEMORRHAGE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; GENE; HETEROZYGOTE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; NEUROIMAGING; NEUROLOGIC DISEASE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RADIATION ATTENUATION; RETROSPECTIVE STUDY; SYMPTOM; TREATMENT RESPONSE;

EID: 84863754358     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.12.42     Document Type: Note

References (46)

1. Sperling R, Salloway S, Brooks DJ et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11(3), 241-249 (2012).
2. Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin. Biol. Ther. 10(7), 1121-1130 (2010).
3. Panza F, Frisardi V, Imbimbo BP et al. Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. Curr. Alzheimer Res. 8(8), 808-817 (2011).
4. Frisardi V, Solfrizzi V, Imbimbo PB et al. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting β-amyloid. Curr. Alzheimer Res. 7(1), 40-55 (2010).
5. Mangialasche F, Solomon A, Winblad B et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9(7), 702-716 (2010).
6. Panza F, Frisardi V, Solfrizzi V et al. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to τ-based immunization strategies. Immunotherapy 4(2), 213-238 (2012).
7. Jicha GA. Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'? Expert Opin. Biol. Ther. 9(4), 481-491 (2009).
8. Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8), 916-919 (2000).
9. Cattepoel S, Hanenberg M, Kulic L, Nitsch RM. Chronic intranasal treatment with an anti-Aβ (30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS ONE 6(4), E18296 (2011).
10. Imbimbo BP, Ottonello S, Frisardi V et al. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev. Clin. Immunol. 8(2), 135-149 (2012).
11. Sperling RA, Jack CR, Black SE et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research. Roundtable Workgroup. Alzheimers Dement. 7(4), 367-285 (2011).
12. Black RS, Sperling RA, Safirstein B et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 24(2), 198-203 (2010).
13. Salloway S, Sperling R, Gilman S et al. A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73(24), 2061-2070 (2009).
14. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a Phase II, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9(4), 363-372 (2010).
15. Carlson C, Estergard W, Oh J et al. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from Phase III trials of semagacestat and solanezumab. Alzheimers Dement. 7(4), 396-401 (2011).
16. Oh U, Gupta R, Krakauer JW, Kahandji AG, Chin SS, Elkind MS. Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology 62(3), 494-497 (2004).
17. Kinnecom C, Lev MH, Wendell L et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 68(17), 1411-1416 (2007).
18. Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads. Expert Opin. Biol. Ther. 11(6), 679-686 (2011).
19. Ostrowitzki S, Deptula D, Thurfjell L et al. Mechanism of amyloid removal in patients with alzheimer disease treated with gantenerumab. Arch. Neurol. 69(2), 198-207 (2012).
20. Boche D, Zotova E, Wller RO et al. Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain. Brain 131(Pt 12), 3299-3310 (2008).
21. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-β peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 18(2), 253-266 (2008).
22. Eng JA, Frosch MP, Choi K, Rebeck W, Greenberg SM. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann. Neurol. 55(2), 250-256 (2004).
23. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6(3), 131-144 (2010).
24. Blennow K, Zetterberg H, Rinne JO et al.; for the AAB-001 201/202 Investigators. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. doi:10.1001/archneurol.2012.90 (2012) (Epub ahead of print).
25. Holmes C, Boche D, Wilkinson D et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled Phase I trial. Lancet 372(9634), 216-223 (2008).
26. Siemers E. Evaluating semagacestat, aγ-secretase inhibitor, in a Phase III trial. Presented at: Alzheimer's Association International Conference 2011. Paris, France, 16-21 July 2011.
27. Bateman RJ, Siemers ER, Mawuenyega KG et al. A γ-secretase inhibitor decreases amyloid-b production in the central nervous system. Ann. Neurol. 66(1), 48-54 (2009).
28. Frisardi V, Imbimbo BP. Metabolic-cognitive syndrome: metabolic approach for the management of Alzheimer's disease risk. J. Alzheimers Dis. doi:10.3233/JAD-2012-120811 (2012) (Epub ahead of print).
29. Struble RG, Ala T, Patrylo PR et al. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? J. Alzheimers Dis. 22(2), 393-399 (2010).
30. Vossel KA, Zhang K, Brodbeck J et al. Tau reduction prevents Aβ-induced defects in axonal transport. Science 330(6001), 198 (2010).
31. Duce JA, Tsatsanis A, Cater MA et al. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142(6), 857-867 (2010).
32. Morris JC. Early-stage and preclinical Alzheimer disease. Alzheimer Dis. Assoc. Disord. 19(3), 163-165 (2005).
33. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007).
34. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 263-269 (2011).
35. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 270-279 (2011).
36. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 280-292 (2011).
37. Effect of LY450139 on the Long Term Progression of Alzheimer's Disease.http://clinicaltrials.gov/ct2/show/NCT00594568?term=LY450139&rank=3 (Accessed 4 May 2012).
38. Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo (IDENTITY-2).http://clinicaltrials.gov/ct2/show/ NCT00762411?term=LY450139&rank=2 (Accessed 4 May 2012).
39. Eli Lilly and Co. Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION) NCT00905372.http://clinicaltrials.gov/ct2/show/NCT00905372? term=NCT00905372&rank=1 (Accessed 4 May 2012)
40. Eli Lilly and Co. Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION2) NCT00904683.http://clinicaltrials.gov/ct2/show/ NCT00904683?term=NCT00904683&rank=1 (Accessed 4 May 2012)
41. JANSSEN Alzheimer Immunotherapy Research & Development, LLC. AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease NCT00606476.http://clinicaltrials.gov/ct2/show/ NCT00606476?term=NCT00606476&rank=1 (Accessed 4 May 2012)
42. JANSSEN Alzheimer Immunotherapy Research & Development, LLC. Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) NCT00575055.http://clinicaltrials.gov/ct2/show/NCT00575055?term= NCT00575055&rank=1(Accessed 4 May 2012)
43. Pfizer. Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients NCT00676143.http://clinicaltrials.gov/ct2/show/ NCT00676143?term=NCT00676143&rank=1(Accessed 4 May 2012)
44. JANSSEN Alzheimer Immunotherapy Research & Development, LLC. Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (APOE4 Non-Carrier) NCT00574132.http://clinicaltrials.gov/ct2/show/NCT00574132?term= NCT00574132&rank=1 (Accessed 4 May 2012)
45. Pfizer. Study Evaluating the Efficacy and Safety of Bapineuzumab in Alzheimer Disease Patients NCT00667810.http://clinicaltrials.gov/ct2/show/ NCT00667810?term=NCT00667810&rank=1 (Accessed 4 May 2012)
46. Pfizer Pipeline, August, 2011.www.pfizer.com/files/research/pipeline/ 2011-0811/pipeline-2011-0811.pdf (Accessed 4 May 2012)